Drug-eluting stent technology has shown encouraging efficacy compared to bare metal stents, significantly reducing restenosis and revascularization procedures. Still, there remains a concern for being able to treat ever-increasing complex lesions, ensuring proper healing, and managing dual antiplatelet therapy (DAPT).

1. CORONARY STENT-
SYNERGY
Everolimus-Eluting Platinum Chromium
Coronary Stent System

2. WHAT IS SYNERGY STENT
Composed of metal stent, bioabsorbable polymer coating and drug
coating
Metal stent made of Platinum Chromium Alloy, consisting of platinum,
chromium, iron, nickel, and molybdenum
The drug is released from the stent to reduce restenosis, treat
complex lesions to ensure proper healing and manage dual
antiplatelet therapy (DAPT)

3. POLYMER COATING
The polymer coating is positioned on the outside of the stent (side in
contact with the coronary artery wall)
The polymer carries and protects the drug before and during the
procedure
Once the stent is implanted, it helps control drug release into the
coronary arterial wall
Absorbed by the body in approximately 4 months

4. DRUG COATING
The SYNERGY Stent is coated with Everolimus and polymer
Designed for consistent and controlled release of the drug from the
stent surface into the artery walls
Both the amount and release rate of drug have been selected for
healing and minimizing restenosis
Reducing the need for additional treatment in the stented area
The Everolimus drug is completely eluted with drug is completed
eluted with optimal kinetics at 3 months

5. WHY SYNERGY?
1. Optimal and early healing
2. Minimal polymer exposure
3. Treating complex lesions
4. Exceptional deliverability, enhanced visibility and navigating tight
lesions
5. Exceptional overexpansion while maintaining mechanical
properties

6. 1. OPTIMAL AND EARLY HEALING
Ultra-thin 74-µm struts show more rapid healing compared to thicker
stent strut designs in clinical cases and in preclinical research¹˒²
The Synchrony Bioabsorbable Polymer promote rapid
endothelialization
Lower inflammation rates
1. PRESENTED BY J. M. DE LA TORRE, MD AT EUROPCR 2014.
2. PRESENTATION BY KAZUYUKI YAHAGI, MD; MICHAEL JONER, MD; RENU VIRMANI, MD AT TCT 2014.

7. LOWER INFLAMMATION RATE
In a preclinical model,
SYNERGY BP Stent
demonstrated:
1. Significantly reduced
Early inflammation
versus Bare Metal
Stents (BMS)
2. Significantly reduced
Late inflammation
versus Permanent
Polymer (PP) Stents

8. OPTIMAL
HEALING
• SYNERGY BP Stent has
shown full stent strut
coverage as early as 30-
days in humans and
showed 0% stent
thrombosis in all these
OCT analysis³
3. ADAPTED FROM PRESENTATION BY IDA RIISE BALLEBY, MD AT ACC 2016.

9. OPTIMAL
HEALING
• SYNERGY BP Stent
showed numerically
lowest ST rates
compared to other DES
despite being used in
patients with more
complex disease
SYNERGY™ Stent Safety: ST rates in real-world SCAAR registry
• SYNERGY BP Stent
showed numerically
lowest ST rates
compared to other new-
generation DES despite
use in more complex
patients with AMI
ST rates in SCAAR AMI Subset Definite Stent Thrombosis
• SYNERGY Stent
demonstrated the lowest
ST rates in patients with
ACS
ST rates in real-world SCAAR registry ACS Sub

10. 2. MINIMAL POLYMER EXPOSURE
Polymer is gone shortly after the drug is
completely eluted at 3 months

11. 2. MINIMAL POLYMER EXPOSURE
Not all bioabsorbable polymer stent are created equal

12. 3. TREATING COMPLEX LESIONS
Indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease,
including patients with acute myocardial infarction and patients with concomitant diabetes mellitus due to
discrete de novo native coronary artery lesions
• Acute coronary syndrome
• Unstable angina
• Renal failure
• Coronary bifurcation lesions
• Coronary multi-vessel disease
• Coronary saphenous vein graft lesions
• Coronary artery ostial lesions
• Unprotected left main coronary artery lesions
• Coronary artery total occlusion lesions
• In-stent restenosis in coronary artery lesions

13. 4. EXCEPTIONAL DELIVERABILITY,
ENHANCED VISIBILITY, NAVIGATING
TIGHT LESIONS
Laser-cut hypotube provides exceptional deliverability by improving pushability
and trackability
PtCr alloy provides excellent visibility for accurate stent placement and assessing
malaposed struts

14. 5. EXCEPTIONAL OVEREXPANSION
WHILE MAINTAINING MECHANICAL
PROPERTIES
Wide range of labeled post-dilation limits

15. 5. EXCEPTIONAL OVEREXPANSION
WHILE MAINTAINING MECHANICAL
PROPERTIES
The SYNERGY large vessel model becomes stronger as it is expanded to its over-expansion

16. 5. EXCEPTIONAL OVEREXPANSION
WHILE MAINTAINING MECHANICAL
PROPERTIES
Robust design for bifurcation
stenting
The 2-connector design throughout
the body maximizes side cell
expansion capabilities and provides
flexibility for bifurcation stenting
Fewer connectors minimize chance
of having a connector obstructing
the side branch, providing better
side branch access